| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e57d76e408ba519a4c9a74769cefa95 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
1999-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25ba4e26f9105371c373d881eaa51bea |
| publicationDate |
2001-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2001131088-A |
| titleOfInvention |
Syndrome X syndrome therapeutic agent |
| abstract |
(57) [Problem] To provide a preventive and / or therapeutic agent for Syndrome X syndrome and the like. An anti-TXA2 compound is used as a preventive and / or therapeutic agent for Syndrome X syndrome. Anti-TXA The two compounds alone can be a prophylactic / therapeutic agent for insulin-resistant diabetes and a prophylactic / therapeutic agent for hyperlipidemia. Furthermore, the anti-TXA2 compound stabilizes atherosclerotic lesions, and thus can be a prophylactic / therapeutic agent for arteriosclerosis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2005063250-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2005074938-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2005529903-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4783152-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8729124-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4688681-B2 |
| priorityDate |
1999-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |